187 related articles for article (PubMed ID: 37356959)
1. [Research Progress on Gene Mutation and CHIP in Pathogenesis of MDS --Review].
He M; Wu T
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):907-910. PubMed ID: 37356959
[TBL] [Abstract][Full Text] [Related]
2. Impact of chromosome alterations, genetic mutations and clonal hematopoiesis of indeterminate potential (CHIP) on the classification and risk stratification of MDS.
Ganguly BB; Banerjee D; Agarwal MB
Blood Cells Mol Dis; 2018 Mar; 69():90-100. PubMed ID: 29079134
[TBL] [Abstract][Full Text] [Related]
3. [MDS: Recent progress in molecular pathogenesis and clinical aspects].
Harada H
Rinsho Ketsueki; 2017; 58(10):1941-1950. PubMed ID: 28978836
[TBL] [Abstract][Full Text] [Related]
4. Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes.
Nakajima H
Intern Med; 2021 Jan; 60(1):15-23. PubMed ID: 32009100
[TBL] [Abstract][Full Text] [Related]
5. Mutations of myelodysplastic syndromes (MDS): An update.
Ganguly BB; Kadam NN
Mutat Res Rev Mutat Res; 2016; 769():47-62. PubMed ID: 27543316
[TBL] [Abstract][Full Text] [Related]
6. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
Jhanwar SC
Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
[TBL] [Abstract][Full Text] [Related]
7. LEP promoter methylation in the initiation and progression of clonal cytopenia of undetermined significance and myelodysplastic syndrome.
Kaastrup K; Gillberg L; Mikkelsen SU; Ørskov AD; Schöllkopf C; Mortensen BK; Porse B; Hansen JW; Grønbæk K
Clin Epigenetics; 2023 May; 15(1):91. PubMed ID: 37237325
[TBL] [Abstract][Full Text] [Related]
8. The Genetics of Myelodysplastic Syndromes: Clinical Relevance.
Chiereghin C; Travaglino E; Zampini M; Saba E; Saitta C; Riva E; Bersanelli M; Della Porta MG
Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440317
[TBL] [Abstract][Full Text] [Related]
9. Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy.
Gill H; Leung AY; Kwong YL
Int J Mol Sci; 2016 Mar; 17(4):440. PubMed ID: 27023522
[TBL] [Abstract][Full Text] [Related]
10. The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP).
Malcovati L; Cazzola M
Hematology Am Soc Hematol Educ Program; 2015; 2015():299-307. PubMed ID: 26637737
[TBL] [Abstract][Full Text] [Related]
11. The molecular basis and clinical significance of genetic mutations identified in myelodysplastic syndromes.
Zhang L; Padron E; Lancet J
Leuk Res; 2015 Jan; 39(1):6-17. PubMed ID: 25465125
[TBL] [Abstract][Full Text] [Related]
12. Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome.
Naqvi K; Sasaki K; Montalban-Bravo G; Alfonso Pierola A; Yilmaz M; Short N; Assi R; Jabbour E; Ravandi F; Kadia T; Pierce S; Takahashi K; Nogueras Gonzalez G; Kanagal-Shamanna R; Patel K; Soltysiak KA; Kantarjian HM; Garcia-Manero G
Cancer; 2019 Jul; 125(13):2233-2241. PubMed ID: 30861111
[TBL] [Abstract][Full Text] [Related]
13. ICUS/CCUS/CHIP: basics & beyond.
Jain M; Tripathi A
Expert Rev Hematol; 2017 Oct; 10(10):915-920. PubMed ID: 28832236
[TBL] [Abstract][Full Text] [Related]
14. Genetics of MDS.
Ogawa S
Blood; 2019 Mar; 133(10):1049-1059. PubMed ID: 30670442
[TBL] [Abstract][Full Text] [Related]
15. [Research progress on mechanism of MDS transformation into AML].
Wang LL; Gao C; Chen BA
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):254-9. PubMed ID: 21362264
[TBL] [Abstract][Full Text] [Related]
16. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
[TBL] [Abstract][Full Text] [Related]
17. Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges.
Caponetti GC; Bagg A
Int J Lab Hematol; 2020 Dec; 42(6):671-684. PubMed ID: 32757473
[TBL] [Abstract][Full Text] [Related]
18. Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis.
Matos A; Magalhães SMM; Rauh MJ
Adv Exp Med Biol; 2021; 1326():1-10. PubMed ID: 33385175
[TBL] [Abstract][Full Text] [Related]
19. The genetic and molecular pathogenesis of myelodysplastic syndromes.
Shallis RM; Ahmad R; Zeidan AM
Eur J Haematol; 2018 Sep; 101(3):260-271. PubMed ID: 29742289
[TBL] [Abstract][Full Text] [Related]
20. [Clonal hematopoiesis in aplastic anemia and paroxysmal nocturnal hemoglobinuria].
Makishima H
Rinsho Ketsueki; 2022; 63(9):1042-1045. PubMed ID: 36198527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
